SIMRIS_B: Simris Group pivots to biopharma but faces urgent liquidity challenges and going concern risks

About this update from Simris Group Ab Class B

Simris Group deepened its focus on biopharma and ADC payloads in 2024, but continued to post losses and faces significant liquidity risks, requiring new capital to sustain operations through 2025. Auditors highlight material uncertainty about going concern. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Simris Group Ab Class B